Kailera Therapeutics, Inc.
NASDAQ:KLRABiotechnology
+$0.51 today
- Market cap
- $1.53B
- Beta
- 0.00
Volume 0.42M
Average 0.80M
KLRA Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Kailera Therapeutics, Inc.NASDAQ: KLRA
Other Income / Expenses · Q2 FY2026 · quarter ended Jun 2026
Other income / expenses of $10.07M in Q2 FY2026
Q2 FY2026 other income / expenses was $10.07M.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 9.39M USD
- Year-over-year change
- —
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.39M | — |
Other Income / Expenses vs competitors
How KLRA compares with its peers on the latest reported figures
- KLRA's FY2025 other income / expenses of $9.39M is the 6th highest of the 10 companies compared; the peer median is $11.78M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $146.07M | +1533.0% | +213.5% | — | |
| LTM Jun 2026 | $25.23M | -38.9% | +182.9% | — | |
| LTM Mar 2026 | $21.62M | +427.9% | +121.1% | — | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $15.24M | +46.9% | — | — |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $11.78M | +9.2% | +266.7% | 114.2% |
KLRAKailera Therapeutics, Inc. | FY2025 | $9.39M | — | — | — |
| LTM Mar 2026 | $5.84M | -19.7% | +26.4% | 16213.9% | |
| LTM Mar 2026 | $2.31M | +7.4% | — | 6.3% | |
| LTM Jun 2026 | -$15.1M | -313.4% | — | 212.0% | |
| LTM Mar 2026 | -$15.12M | -297.9% | — | — | |
| Peer median (excluding KLRA) | $11.78M | +7.4% | +182.9% | 163.1% | |
Competitors are the stored peer set for KLRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | 0 |
| Gross Profit | 0 |
| Gross Margin | — |
| Research & Development | 109.11M |
| Selling, General & Admin | 49.23M |
| Operating Expenses | 158.34M |
| Depreciation & Amortization | 310K |
| EBITDA | (158.03M) |
| EBITDA Margin | — |
| Operating Income | (158.34M) |
| Operating Margin | — |
| Interest Income | 11.05M |
| Interest Expense | 0 |
| Other Income / Expenses | 9.39M |
| Income Before Tax | (148.96M) |
| Pre-Tax Margin | — |
| Income Tax Expense | 0 |
| Net Income | (148.96M) |
| Net Margin | — |
| EPS (Basic) | (1.26) |
| EPS (Diluted) | (1.26) |
| Weighted Avg Shares | 117.95M |
| Weighted Avg Shares (Diluted) | 117.95M |
Kailera Therapeutics, Inc.
NASDAQ:KLRA
Intrinsic Alpha fair value
Locked
Current Price
$11.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.